Eylea and Retinal vasculitis - a phase IV clinical study of FDA data

Summary:

Retinal vasculitis is reported as a side effect among people who take Eylea (aflibercept), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Beovu, and have Age-related macular degeneration.

The phase IV clinical study analyzes which people have Retinal vasculitis when taking Eylea. It is created by eHealthMe based on reports of 27,819 people who have side effects when taking Eylea from the FDA, and is updated regularly.

What is Eylea?

Eylea has active ingredients of aflibercept. It is often used in macular degeneration. eHealthMe is studying from 27,868 Eylea users. Check the latest studies of Eylea.

What is Retinal vasculitis?

Retinal vasculitis (a sight-threatening inflammatory eye condition that involves the retinal vessels) is found to be associated with 68 drugs and 146 conditions by eHealthMe. Check the latest studies of Retinal vasculitis.

On Jul, 09, 2026

27,819 people reported to have side effects when taking Eylea.
Among them, 95 people (0.34%) have Retinal vasculitis.

Among these 95 people:

How long have people been on Eylea when they have Retinal vasculitis? *

What is the gender of people who have Retinal vasculitis when taking Eylea? *

female: 56.94 %
male: 43.06 %

What is the age of people who have Retinal vasculitis when taking Eylea? *

What are other drugs people take besides Eylea? *

What are other side effects people have besides Retinal vasculitis? *

Vitritis (inflammation of the vitreous humour of the eye): 29 people, 30.53%
Vitreous Floaters (spots before the eyes): 29 people, 30.53%
Eye Inflammation: 27 people, 28.42%
Vision Blurred: 27 people, 28.42%
Visual Acuity Reduced (reduced clearness of vision): 26 people, 27.37%
Uveitis (inflammation of the uvea): 25 people, 26.32%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 25 people, 26.32%
Visual Impairment: 22 people, 23.16%
Retinal Vascular Occlusion (a blockage of the small veins that carry blood away from the retina): 20 people, 21.05%
Blindness: 16 people, 16.84%

What are the existing conditions these people have? *

Age-Related Macular Degeneration: 36 people, 37.89%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 8 people, 8.42%
Choroidal Neovascularisation (creation of new blood vessels in vascular layer of eye): 7 people, 7.37%
High Blood Pressure: 6 people, 6.32%
Polypoidal Choroidal Vasculopathy (polyp-like sub-retinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region): 5 people, 5.26%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 3 people, 3.16%
Type 2 Diabetes: 3 people, 3.16%
Dry Eyes (lack of adequate tears): 3 people, 3.16%
Varicose Vein (veins that have become enlarged and tortuous): 2 people, 2.11%
Conjunctivitis (pink eye): 2 people, 2.11%

* Approximation only. Some reports may have incomplete information.

Do you take Eylea and have Retinal vasculitis?

- Check whether Retinal vasculitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Eylea:

Eylea (27,868 reports)

Browse all side effects of Eylea:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Retinal vasculitis:

Retinal vasculitis (68 drugs)

Browse all the conditions that are associated with Retinal vasculitis:

Retinal vasculitis (146 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on aflibercept (the active ingredients of Eylea) and Eylea (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.